CAC Progression Doesn't Improve Prediction of CVD Events

This article originally appeared here.
Share this content:
CAC Progression Doesn't Improve Prediction of CVD Events
CAC Progression Doesn't Improve Prediction of CVD Events

THURSDAY, July 7, 2016 (HealthDay News) -- Coronary artery calcification (CAC) progression is no better for predicting cardiovascular disease (CVD) events than follow-up CAC, according to a study published in the June issue of the Journal of the American College of Cardiology: Cardiovascular Imaging.

Nina B. Radford, M.D., from the Cooper Clinic in Dallas, and colleagues examined whether CAC progression is a useful predictor of future CVD events in a prospective observational study involving 5,933 participants free of CVD.

The researchers detected CAC in 48 percent of individuals at baseline. Participants underwent two scans, with an average time between scans of 3.5±2 years. During a mean follow-up of 7.3 years, 161 individuals experienced a total CVD event after their second scan. There was a significant correlation between CAC progression and total CVD events (hazard ratio, 1.14; 95 percent confidence interval, 1.01 to 1.3 per interquartile range) in a model including baseline CAC; the relative contribution of CAC progression versus baseline CAC was small. In the model including follow-up rather than baseline CAC, CAC progression was not associated with total CVD events (hazard ratio, 1.05; 95 percent confidence interval, 0.92 to 1.21). Performance was similar for a model that included follow-up CAC alone and a model that included baseline CAC and CAC progression.

"These findings imply that if serial CAC scanning is performed, the latest scan should be used for risk assessment, and in this context, CAC progression provides no additional prognostic information," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »